News >

Byrd Highlights Ibrutinib's Continued Progress in CLL

Gina Columbus @ginacolumbusonc
Published: Monday, Jun 12, 2017

John C. Byrd, MD

John C. Byrd, MD

A 4-year follow-up of the RESONATE study, comparing the BTK inhibitor ibrutinib (Imbruvica) to ofatumumab (Arzerra), continues to demonstrate ibrutinib’s benefit in patients with chronic lymphocytic leukemia (CLL) who had at least 1 prior therapy.

during the 2017 ASCO Annual Meeting, Byrd shed light on the game-changing efficacy of ibrutinib in CLL.

OncLive: Can you discusse the updated findings from the RESONATE study presented at this meeting?

Byrd: The RESONATE study is the first randomized phase III study that reported out the first-in-class irreversible inhibitor ibrutinib. This was a randomized trial that compared ibrutinib in second or greater line to ofatumumab, a standard of care for patients with CLL at that time. Patients were randomized to 1 or the other therapy; at the initial part of the trial, there was not a crossover. After it was clear that ibrutinib had significant activity, loss of equipoise existed for the control, and a crossover was allowed. What was presented at the 2017 ASCO Annual Meeting was long-term follow-up—a median of 45 months for most patients and, for some patients, out as far as 4.5 years. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication